DiscoveryProbe™ FDA-approved Drug Library: Accelerating High-Throughput Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds approved by major regulatory agencies, supporting high-throughput and high-content screening workflows (ApexBio, 2024). The library includes compounds with diverse mechanisms of action, such as receptor agonists, enzyme inhibitors, and ion channel modulators, enabling the identification of novel therapeutic targets (ApexBio, 2024). All compounds are pre-dissolved at 10 mM in DMSO, ensuring stability for up to 24 months at -80°C (ApexBio, 2024). The library has been used to identify FDA-approved drugs acting as TSHR antagonists, illustrating its value in drug repositioning (Guo et al., 2025, https://doi.org/10.1210/clinem/dgae732). Its integration into HTS and HCS workflows accelerates the path from screening to mechanistic validation (ApexBio, 2024).

Biological Rationale

The DiscoveryProbe™ FDA-approved Drug Library addresses the urgent need for efficient drug discovery and repositioning. Drug repositioning, the identification of new indications for existing drugs, reduces development time and cost compared to de novo drug discovery (Guo et al., 2025). FDA-approved compounds offer established safety and pharmacokinetic profiles, streamlining translational research. The library covers a spectrum of pharmacological classes, including kinase inhibitors, anti-infectives, and metabolic regulators. Representative compounds, such as doxorubicin, metformin, and atorvastatin, target diseases ranging from cancer to diabetes. Screening clinically approved drugs has enabled the identification of thyrotropin receptor (TSHR) antagonists, relevant to thyroid eye disease (TED) and other autoimmune conditions (Guo et al., 2025). By providing a standardized, regulatory-vetted compound set, the DiscoveryProbe™ library facilitates reproducible target identification and mechanistic studies across diverse biomedical applications.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library contains compounds that modulate a wide range of biological targets. These include:

• Receptor agonists and antagonists: Compounds modulating GPCRs, ion channels, and nuclear receptors.
• Enzyme inhibitors: Molecules targeting kinases, proteases, and metabolic enzymes.
• Signal pathway modulators: Agents regulating MAPK, PI3K/AKT, Wnt, and other pathways.
• Ion channel modulators: Drugs affecting voltage- and ligand-gated channels.

For example, 2′-O-galloylhyperin, identified via structure-based virtual screening of FDA-approved drugs, functions as a TSHR antagonist and inhibits the cAMP signaling pathway in orbital fibroblasts (Guo et al., 2025). The library's coverage enables systematic interrogation of disease models, elucidating the roles of pharmacological classes in cell signaling, proliferation, differentiation, and fibrosis. Each compound is quality-controlled and provided in a 10 mM DMSO solution, compatible with robotic liquid handling and high-throughput formats.

Evidence & Benchmarks

• Structure-based virtual screening using FDA-approved drugs identified 2′-O-galloylhyperin as a TSHR antagonist that inhibits cAMP signaling and fibroblast proliferation in TED models (Guo et al., 2025).
• The DiscoveryProbe™ library supports robust, reproducible high-throughput screening workflows for target identification and mechanistic studies (HDAC1.com).
• Use of library compounds enables the identification of approved drugs with novel anti-fibrotic and anti-adipogenic effects in disease-relevant cell models (Guo et al., 2025).
• All compounds are stable for 12 months at -20°C and up to 24 months at -80°C, supporting extended experimental timelines (ApexBio, 2024, product page).
• The library has enabled drug repositioning studies in oncology, neurodegeneration, and metabolic disease, with validated hits proceeding to in vitro and in vivo validation (MoleculeProbe.com).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library enables:

• High-throughput screening (HTS): Efficient identification of active compounds in disease models.
• High-content screening (HCS): Multiparametric phenotypic analysis in cellular and organoid systems.
• Drug repositioning: Discovery of new indications for existing drugs, reducing translational barriers (AmericaPeptide.com).
• Pharmacological target identification: Mechanistic deconvolution via annotated compound effects.

This article extends prior summaries (HDAC1.com) by providing detailed evidence of disease-relevant target discovery, such as TSHR antagonism in TED, and clarifies the mechanistic diversity of the compound set. In contrast to MoleculeProbe.com, which focuses on workflow acceleration, this article benchmarks empirical outcomes in cell-based models and highlights stability and storage conditions.

Common Pitfalls or Misconceptions

• The library is not designed for direct clinical use; all findings require further preclinical validation.
• Not all compounds are active in every cell type or disease model; negative results may reflect biological specificity, not compound inactivity.
• Compounds are dissolved in DMSO; final DMSO concentration should be controlled in assays to avoid solvent toxicity artifacts.
• HTS results may require orthogonal validation; hits from screening should be confirmed by secondary assays.
• The resource does not include investigational or preclinical compounds; only drugs with regulatory approval or pharmacopeia listing are present.

Workflow Integration & Parameters

The DiscoveryProbe™ library is engineered for seamless integration into automated screening platforms. Features include:

• Pre-dissolved 10 mM DMSO solutions for direct pipetting.
• Multiple formats: 96-well microplates, deep well plates, and 2D barcoded screw-top storage tubes.
• Stability: 12 months at -20°C, 24 months at -80°C, per manufacturer guidelines (product page).
• Shipping: on blue ice for evaluation samples; room temperature or blue ice for other formats.
• Compatibility: Validated with HTS and HCS protocols, including cell-based and biochemical assays.
• Documentation: Each lot is accompanied by compound annotation, regulatory status, and chemical structure data.

Compared to prior overviews (BKM120.net), this article emphasizes practical storage, handling, and data annotation, enabling reproducibility and traceability in large-scale screening campaigns.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library is a high-value resource for drug repositioning, mechanistic target identification, and high-throughput screening. Its rigorously curated, stability-validated compound set accelerates translational research by leveraging the clinical track record of approved drugs. Empirical studies, such as the identification of 2′-O-galloylhyperin as a TSHR antagonist, demonstrate the library's capacity for uncovering unanticipated therapeutic opportunities (Guo et al., 2025). As screening technologies advance, the integration of regulatory-grade libraries like DiscoveryProbe™ will continue to enhance the efficiency and reliability of drug discovery pipelines.